Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma

被引:0
|
作者
Gross, N [1 ]
Balmas, K
Brognara, CB
Tschopp, J
机构
[1] CHU Vaudois, Univ Hosp, Oncohematol Unit, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 2001年 / 36卷 / 01期
关键词
neuroblastoma; Fas receptor; apoptosis;
D O I
10.1002/1096-911X(20010101)36:1<111::AID-MPO1026>3.0.CO;2-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Procedure. To determine the possible role of Fas/FasL system in the particularly heterogeneous behaviour of neuroblastoma d(NB), we have measured the functional expression of Fas and its ligand, FasL, in primary neuroblastoma samples and cell lines by immunohistochemistry and flow cytometry. Results. Our results reveal that while Fas expression is associated with low stage and more mature tumors, heterogeneous FasL expression was mostly detected in high stage tumors, with-our apparent correlation to MYCN amplification. Flow cytometric analysis of cell lines demonstrated a high expression of Fas in epithelial-type, HLA class I positive cell lines, which was lost upon activation with phorbol esters. In contrast, Fas ligand was detected in only a small subset of cell lines. Conclusions. In some cell lines, cytotoxic assays revealed the ability of NB-associated Fas receptor to transduce an apoptotic signal upon triggering. The pattern of functional Fas/FasL expression in tumours and cell lines suggests that this system may be involved in the evasion of highly malignant neuroblastoma cells to host immune response. Med. Pediatr. Oncol. 36:111-114, 2001. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:111 / 114
页数:4
相关论文
共 50 条
  • [31] REGULATION OF CELL-SURFACE APO-1/FAS (CD95) LIGAND EXPRESSION BY METALLOPROTEASES
    MARIANI, SM
    MATIBA, B
    BAUMLER, C
    KRAMMER, PH
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (08) : 2303 - 2307
  • [32] Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer
    Gratas, C
    Tohma, Y
    Barnas, C
    Taniere, P
    Hainaut, P
    Ohgaki, H
    CANCER RESEARCH, 1998, 58 (10) : 2057 - 2062
  • [33] The CD95(APO-1/Fas)/CD95L system
    Krammer, PH
    TOXICOLOGY LETTERS, 1998, 103 : 131 - 137
  • [34] Expression of fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege
    O'Connell, J
    Bennett, MW
    O'Sullivan, GC
    O'Callaghan, J
    Collins, JK
    Shanahan, F
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1999, 6 (04) : 457 - 463
  • [35] Localization and expression of Fas (CD95) ligand (FasL) and Fas receptor (Fas) in the rat epididymis
    Griffin, FC
    Lowe, DA
    Lund, T
    Cameron, DF
    FASEB JOURNAL, 1997, 11 (03): : 3569 - 3569
  • [36] CD95 (APO-1/Fas)-associating signalling proteins
    Peter, ME
    Kischkel, FC
    Hellbardt, S
    Chinnaiyan, AM
    Krammer, PH
    Dixit, VM
    CELL DEATH AND DIFFERENTIATION, 1996, 3 (02): : 161 - 170
  • [37] CD95 (APO-1/FAS) AND THE CD95 LIGAND IN NORMAL AND MALIGNANT B-CELL APOPTOSIS
    DANIEL, PT
    MAPARA, MY
    BOMMERT, K
    BARGOU, RC
    KRAMMER, P
    DORKEN, B
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 831 - 831
  • [38] Two CD95 (APO-1/Fas) signaling pathways
    Scaffidi, C
    Fulda, S
    Srinivasan, A
    Friesen, C
    Li, F
    Tomaselli, KJ
    Debatin, KM
    Krammer, PH
    Peter, ME
    EMBO JOURNAL, 1998, 17 (06): : 1675 - 1687
  • [39] Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes
    D Bouscary
    J De Vos
    M Guesnu
    K Jondeau
    F Viguier
    J Melle
    F Picard
    F Dreyfus
    M Fontenay-Roupie
    Leukemia, 1997, 11 : 839 - 845
  • [40] CD95 (APO-1/Fas) and Parkinson's disease
    Hartmann, A
    Hunot, S
    Hirsch, EC
    Hirsch, C
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 425 - 425